1. Home
  2. SSKN vs PHGE Comparison

SSKN vs PHGE Comparison

Compare SSKN & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSKN
  • PHGE
  • Stock Information
  • Founded
  • SSKN 1989
  • PHGE 2015
  • Country
  • SSKN United States
  • PHGE Israel
  • Employees
  • SSKN N/A
  • PHGE N/A
  • Industry
  • SSKN Medical/Dental Instruments
  • PHGE Biotechnology: Pharmaceutical Preparations
  • Sector
  • SSKN Health Care
  • PHGE Health Care
  • Exchange
  • SSKN Nasdaq
  • PHGE Nasdaq
  • Market Cap
  • SSKN 8.9M
  • PHGE 10.4M
  • IPO Year
  • SSKN 2005
  • PHGE N/A
  • Fundamental
  • Price
  • SSKN $1.70
  • PHGE $0.52
  • Analyst Decision
  • SSKN Strong Buy
  • PHGE Strong Buy
  • Analyst Count
  • SSKN 1
  • PHGE 1
  • Target Price
  • SSKN $6.00
  • PHGE $15.00
  • AVG Volume (30 Days)
  • SSKN 2.8M
  • PHGE 1.6M
  • Earning Date
  • SSKN 08-13-2025
  • PHGE 08-13-2025
  • Dividend Yield
  • SSKN N/A
  • PHGE N/A
  • EPS Growth
  • SSKN N/A
  • PHGE N/A
  • EPS
  • SSKN N/A
  • PHGE N/A
  • Revenue
  • SSKN $32,848,000.00
  • PHGE N/A
  • Revenue This Year
  • SSKN N/A
  • PHGE N/A
  • Revenue Next Year
  • SSKN $9.70
  • PHGE N/A
  • P/E Ratio
  • SSKN N/A
  • PHGE N/A
  • Revenue Growth
  • SSKN 0.36
  • PHGE N/A
  • 52 Week Low
  • SSKN $1.61
  • PHGE $0.34
  • 52 Week High
  • SSKN $3.86
  • PHGE $1.23
  • Technical
  • Relative Strength Index (RSI)
  • SSKN 43.89
  • PHGE 49.99
  • Support Level
  • SSKN $1.61
  • PHGE $0.49
  • Resistance Level
  • SSKN $3.86
  • PHGE $0.56
  • Average True Range (ATR)
  • SSKN 0.36
  • PHGE 0.04
  • MACD
  • SSKN 0.03
  • PHGE -0.00
  • Stochastic Oscillator
  • SSKN 4.00
  • PHGE 45.57

About SSKN Strata Skin Sciences Inc.

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: